GlassScriptPhysician profile
Arvinder Thiara
NPI 1063587616
$406.61
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $17.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $117.99 | 2019 | |
| Ironshore Pharmaceuticals INC. | $93.55 | 2019 | |
| Merck Sharp & Dohme LLC | $38.47 | 2019 | |
| Sanofi Pasteur INC. | $28.33 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.61 | 2019 | |
| Novo Nordisk INC | $22.15 | 2019 | |
| Glaxosmithkline, LLC. | $18.09 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.04 | 2019 | |
| Abbvie INC. | $17.16 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.22 | 2019 | |
| Pfizer INC. | $12.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvinder Thiara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.